During a live event, Yelena Y. Janjigian, MD, moderated a discussion on how to use PD-L1 CPS status when considering ...
CytoDyn (CYDY) announced that breast cancer specialist and medical oncologist, Milana V. Dolezal, MD, MSci, is presenting a poster entitled ...
Sac-TMT combined with Keytruda significantly improves progression-free survival in PD-L1-positive advanced non-small cell lung cancer. The OptiTROP-Lung05 study is the first phase 3 trial of an ...
BioNTech (BNTX) and Bristol Myers Squibb Company (BM) announced the first interim data from a global randomized Phase 2 trial evaluating pumitamig, an investigational bispecific antibody targeting ...
BioNTech and Bristol Myers Squibb share positive data from Phase 2 trial of pumitamig plus chemotherapy for triple-negative ...
Global interim Phase 2 data in locally advanced/metastatic triple-negative breast cancer (”TNBC”) show encouraging antitumor activity for ...
Leronlimab treatment is associated with upregulation of PD-L1 in circulating tumor cells and cancer-associated macrophage-like cellsRemarkably ...
The main market opportunities for PD-L1 x 4-1BB bispecific antibodies lie in their ability to enhance antitumor responses while minimizing liver toxicity by focusing activation within the tumor ...
Recently, the research group of Prof. HUANG Qing at Hefei Institutes of Physical Science, Chinese Academy of Sciences developed DNA-aptamer based surface enhanced Raman spectroscopy (SERS) probes for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback